Neuraxis (NRXS) Gross Margin (2022 - 2025)

Neuraxis (NRXS) posted Gross Margin of 85.37% for Q4 2025, up 2.48% sequentially from 83.3% in Q3 2025, and down 83.0% YoY from 502.17% in Q4 2024.

Neuraxis (NRXS) Gross Margin (2022 - 2025) Analysis & Trends

Neuraxis has reported Gross Margin for 4 years, with the latest figure at 85.37% in Q4 2025.

Quarterly Gross Margin fell 83.0% year-over-year to 85.37% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 84.22% (down 273.0% YoY) and the FY2025 annual result came in at 84.23%, down 229.0% from the prior year.
Gross Margin rose to 85.37% in Q4 2025 per NRXS's latest filing, from 83.3% in the prior quarter.
Over five years, Gross Margin peaked at 89.5% in Q2 2023 and troughed at 83.3% in Q3 2025.
A 4-year average of 86.66% and a median of 86.39% in 2023 frame the typical range for Gross Margin.
The sharpest annual moves came in 2023 and 2025: Gross Margin soared 108 bps in 2023, then tumbled 439 bps in 2025.
Over 4 years, Gross Margin stood at 87.73% in 2022, then dropped by 2 bps to 86.39% in 2023, then retreated by 0 bps to 86.2% in 2024, then fell by 1 bps to 85.37% in 2025.
According to Business Quant data, Gross Margin over the past three periods registered 85.37%, 83.3%, and 83.6% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	91.59%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	90.43%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	35.86%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	76.90%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	84.20%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	63.27%
10	Neuraxis	75.51 Mn	67.18 Mn	-	-

Download Data